Heat Biologics Inc. and Oncosec Medical Inc. are joining forces to evaluate the preclinical efficacy of combining Heat's tumor-specific cytotoxic T-cell immunotherapy with Oncosec's Immunopulse intratumoral DNA delivery platform in a bid to expand the impact of their technologies for the benefit of people with cancer.
VBL Therapeutics shares (NASDAQ:VBLT) plummeted 65.5 percent Tuesday to $4.87, more than a dollar under the company's recent initial public offering (IPO) price, as investors digested news that VB-201, an experimental autoimmune therapy that had appeared to help patients with psoriasis in an earlier midstage study, failed to significantly benefit both psoriasis and ulcerative colitis sufferers in separate phase II trials.
About a year after its last public offering, Idera Pharmaceuticals Inc. priced a $75 million public offering Friday to advance ongoing and upcoming trials of IMO-8400, its lead Toll-like receptor antagonist candidate in development for the treatment of Waldenström's macroglobulinemia, diffuse large B-cell lymphoma (DLBCL), dermatomyositis and Duchenne muscular dystrophy (DMD).
Updated interim phase II data showing that a combination of Achillion Pharmaceuticals Inc.'s NS5A inhibitor, ACH-3102, and Sovaldi (sofosbuvir, Gilead Sciences Inc.) cleared hepatitis C virus (HCV) in 100 percent of 12 genotype 1 patients after just six weeks of treatment – the shortest of any two-drug, direct-acting antiviral regimen, the company said – pushed shares (NASDAQ:ACHN) up 7.8 percent to $11.66 on Monday.
Ohr Pharmaceutical Inc. is raising $25 million to fund dual pivotal phase III studies of its Lucentis-boosting eye drops, OHR-102 (squalamine), in newly diagnosed patients with AMD.
After nearly five years of building and testing, with the FDA's Mini-Sentinel pilot project nearing the goal of becoming the agency's next-generation safety watchdog tool, experts discussing its future in Washington said they see tremendous potential in its progress to date as well as plenty of work to be done before realizing the program's full potential.
Sales of Gilead Sciences Inc.'s top hepatitis C virus (HCV) drugs continued to boom in the fourth quarter amid new competition, totaling about $3.8 billion, and helping lead the company to a profit more than four times higher than the same quarter last year.
Chimerix Inc.'s decision Friday to cancel trials of its antiviral brincidofovir to protect against Ebola in the face of declining numbers of new infections, and thus dwindling numbers of test subjects, brought into sharp relief the hard choices small companies need to make when choosing to develop experimental treatments for neglected tropical diseases.
Investors flocking to Spark Therapeutics Inc. more that doubled the company's value in a fiery debut that drove shares (NASDAQ:ONCE) of the gene therapy developer's upsized initial public offering (IPO) up 117.4 percent to $50 from its $23 initial offering price.
Rare disease specialist Alexion Pharmaceuticals Inc. is striding ahead with fast-rising sales of its sole approved product, Soliris (eculizumab), and soon a new chief executive, it said in an earnings report Thursday.
